Macular Edema, Visual Acuity
Conditions
Keywords
macular edema, irvine gass syndrome, ozurdex
Brief summary
To analyze macula edema formation after cataract surgery called Irvine-Gass-Syndrome.
Detailed description
20 to 25 patients suffering from Irvine Gass Syndrom should be monitored for at least six months, controlled monthly. In all cases best corrected visual acuity, Spectralis-OCT (volume thickness scan), fundus photography (Optomap), intraocular pressure, slitlamp assessment and indirect ophthalmoscopy should be performed on every visit. Fluorescein angiography should be performed at baseline and after 3 and 6 months. Inclusion criteria: Patients older than 18 years who develop macula edema secondary to cataract surgery. \- Consent agreement - Patients should be informed that it is possible to get an active medication (Ozurdex implant) as an on label indication from the health insurance company if the diagnosis is accepted as an intraocular inflammation form of Uveitis posterior. Exclusion criteria: Visual acuity worse than 20/400, known history of glaucoma and steroid response, any macular disease interfering with visual acuity (DME, AMD, etc.), history of vitrectomy, use of systemic, periocular, or intraocular corticosteroids within 30 days. Outcome: * BCVA * Patients suffering from diabetes mellitus should be evaluated also separately. * Change in central retinal thickness using optical coherence tomography (OCT) * Secondary parameters (elevated IOP, retinal detachments, vitreous hemorrhage, endophthalmitis rates)
Interventions
\- Consent agreement - Patients should be informed that it is possible to get an active medication (Ozurdex implant) as an on label indication from the health insurance company if the diagnosis is accepted as an intraocular inflammation form of Uveitis posterior.
Sponsors
Study design
Eligibility
Inclusion criteria
Patients older than 18 years who develop macula edema secondary to cataract surgery
Exclusion criteria
Visual acuity worse than 20/400, known history of glaucoma and steroid response, any macular disease interfering with visual acuity (DME, AMD, etc.), history of vitrectomy, use of systemic, periocular, or intraocular corticosteroids within 30 days.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Visual acuity | 12 months | Best corrected visual acuity and visual acuity gain after 6 and 12 months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Retinal Thickness | 12 months | Retinal thickness measured by OCT. |
| Intraocular pressure | 12 months | Intraocular pressure using Goldmann applanation tonometer |
Countries
Germany